drugset / Trial / NCT04833582
A Study of Azenosertib (ZN-c3) in Combination With Gemcitabine in Subjects With Osteosarcoma
Phase 1
Completed
31 enrolled
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
NaSequentialOpen-labelTreatment
Summary
This is a phase 1/2 study of azenosertib (ZN-c3) in combination with gemcitabine in adult and pediatric subjects with relapsed or refractory osteosarcoma.
Timeline
- Start
- 2021-08-01
- Primary completion
- 2023-08-30
- Completion
- 2024-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azenosertib | Small molecule | — | — |
| Background | Gemcitabine | Small molecule | — | — |